Technical Analysis for FDMT - 4D Molecular Therapeutics, Inc.

Grade Last Price % Change Price Change
D 23.80 0.72% 0.17
FDMT closed up 0.72 percent on Monday, June 17, 2024, on 84 percent of normal volume.
4 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Flat

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
MACD Bullish Signal Line Cross Bullish 0.00%
Outside Day Range Expansion 0.00%
Calm After Storm Range Contraction 0.72%
NR7 Range Contraction 0.72%
20 DMA Resistance Bearish -2.50%
Calm After Storm Range Contraction -2.50%
Outside Day Range Expansion -2.50%
Up 3 Days in a Row Strength -2.50%
Gapped Down Weakness -2.50%

   Recent Intraday Alerts

Alert Time
10 DMA Resistance about 9 hours ago
Rose Above Previous Day's High about 10 hours ago
20 DMA Resistance about 10 hours ago
Outside Day about 10 hours ago
Up 3% about 10 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


4D Molecular Therapeutics, Inc. Description

4DMT is a clinical-stage gene therapy company pioneering the development of product candidates using targeted and evolved AAV vectors. 4DMT seeks to unlock the full potential of gene therapy using its platform, Therapeutic Vector Evolution, which combines the power of directed evolution with approximately one billion synthetic capsid sequences to invent evolved vectors for use in targeted gene therapy products. The company is initially focused in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The 4DMT targeted and evolved vectors are invented with the goal of being delivered through clinically routine, well-tolerated and minimally invasive routes of administration, transducing diseased cells in target tissues efficiently, having reduced immunogenicity and, where relevant, having resistance to pre-existing antibodies. 4DMT is currently conducting three clinical trials: 4D-125 is in a Phase 1/2 clinical trial for XLRP, 4D-110 is in a Phase 1 clinical trial for choroideremia and 4D-310 is in a Phase 1/2 clinical trial for Fabry disease.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Life Sciences Biology Emerging Technologies Antibodies Molecular Biology Gene Therapy Medical Genetics Gene Delivery Fabry Disease Gene Therapy Products Gene Therapy Of The Human Retina

Is FDMT a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 36.25
52 Week Low 9.44
Average Volume 490,911
200-Day Moving Average 20.51
50-Day Moving Average 25.24
20-Day Moving Average 24.45
10-Day Moving Average 23.91
Average True Range 1.56
RSI (14) 45.95
ADX 9.4
+DI 21.21
-DI 17.09
Chandelier Exit (Long, 3 ATRs) 22.67
Chandelier Exit (Short, 3 ATRs) 26.22
Upper Bollinger Bands 26.83
Lower Bollinger Band 22.07
Percent B (%b) 0.36
BandWidth 19.46
MACD Line -0.56
MACD Signal Line -0.57
MACD Histogram 0.0088
Fundamentals Value
Market Cap 1.17 Billion
Num Shares 49.3 Million
EPS -2.65
Price-to-Earnings (P/E) Ratio -8.98
Price-to-Sales 62.23
Price-to-Book 4.02
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 25.33
Resistance 3 (R3) 25.38 24.93 25.08
Resistance 2 (R2) 24.93 24.54 24.90 24.99
Resistance 1 (R1) 24.36 24.30 24.65 24.31 24.90
Pivot Point 23.91 23.91 24.05 23.88 23.91
Support 1 (S1) 23.34 23.52 23.63 23.29 22.70
Support 2 (S2) 22.89 23.28 22.86 22.61
Support 3 (S3) 22.32 22.89 22.53
Support 4 (S4) 22.27